Suppression of KRas-mutant cancer through the combined inhibition of KRAS with PLK1 and ROCK
KRas is frequently mutated in multiple cancer types; identifying drugs to treat such cancers is a good therapeutic strategy. Here, the authors perform a synthetic lethal screen in mice and show that inhibiting Plk1 and ROCK results in the inhibition of tumour growth by increasing expression of the t...
Main Authors: | Jieqiong Wang, Kewen Hu, Jiawei Guo, Feixiong Cheng, Jing Lv, Wenhao Jiang, Weiqiang Lu, Jinsong Liu, Xiufeng Pang, Mingyao Liu |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2016-05-01
|
Series: | Nature Communications |
Online Access: | https://doi.org/10.1038/ncomms11363 |
Similar Items
-
A combination therapy for KRAS-mutant lung cancer by targeting synthetic lethal partners of mutant KRAS
by: Xiufeng Pang, et al.
Published: (2016-10-01) -
Dual inhibition of VEGF and PARP suppresses KRAS-mutant colorectal cancer
by: Longhui Zhong, et al.
Published: (2020-09-01) -
RAF Suppression Synergizes with MEK Inhibition in KRAS Mutant Cancer Cells
by: Simona Lamba, et al.
Published: (2014-09-01) -
Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy
by: Ke Xu, et al.
Published: (2019-04-01) -
Synergistic effects of FGFR1 and PLK1 inhibitors target a metabolic liability in KRAS‐mutant cancer
by: Zhang Yang, et al.
Published: (2021-09-01)